The neurotology biopharma Otonomy (Nasdaq:OTIC) has announced that the brain-derived neurotrophic factor agonist OTO-413 resulted in clinically meaningful improvement in a Phase 2a trial focused on subjects with hearing loss. In the randomized, double-blind, placebo-controlled study, subjects received a single intratympanic injection of 0.3 mg of OTO-413. Subjects in the study had 30 evaluable subjects…
Investigational tinnitus drug shows promise in Phase 1/2 study
Neurotology drug developer Otonomy (NSDQ:OTIC) has announced that its OTO-313 drug appeared to reduce tinnitus severity in some participants in a small study. In the study, summarized in Otology & Neurotology, patients with moderate to severe unilateral tinnitus received intratympanic administration of the drug or placebo. Six OTO-313 recipients out of 14 (43%) showed a meaningful…
Decibel Therapeutics announces study on noise-related inner ear damage
Decibel Therapeutics (NSDQ:DBTX) has a working hypothesis that molecular characterization of the cell biology of the inner ear could pave the way for treatments for hearing and balance disorders. The Boston-based biotech company has announced that a recent study published in Cell Reports supports that hypothesis. “We were thrilled to leverage our data and expertise in inner…
Otonomy expands Phase 1/2 hearing loss clinical trial
Neurotology drug developer Otonomy (NSDQ:OTIC) is expanding a Phase 1/2 trial of OTO-413 in patients with difficulty with speech-in-noise tests. In the trial, clinical investigators administer the drug as a single intratympanic injection. The company said that OTO-413 showed promise in improving hearing in a dose escalation efficacy cohort. The randomized, double-blind, placebo-controlled Phase 1/2…